KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Palvella Therapeutics (PVLA) over the last 11 years, with Sep 2024 value amounting to $142,000.

  • Palvella Therapeutics' Cash from Investing Activities rose 107.16% to $142,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $14.8 million, marking a year-over-year increase of 52.87%. This contributed to the annual value of $12.0 million for FY2023, which is 156.52% up from last year.
  • Per Palvella Therapeutics' latest filing, its Cash from Investing Activities stood at $142,000 for Q3 2024, which was down 93.47% from $2.2 million recorded in Q2 2024.
  • In the past 5 years, Palvella Therapeutics' Cash from Investing Activities ranged from a high of $18.4 million in Q3 2020 and a low of -$16.9 million during Q1 2022.
  • In the last 3 years, Palvella Therapeutics' Cash from Investing Activities had a median value of $1.1 million in 2022 and averaged $189,455.
  • Examining YoY changes over the last 5 years, Palvella Therapeutics' Cash from Investing Activities showed a top increase of 1,662.86% in 2022 and a maximum decrease of 60,428.57% in 2022.
  • Quarterly analysis of 5 years shows Palvella Therapeutics' Cash from Investing Activities stood at $14.9 million in 2020, then tumbled by 102.30% to -$342,000 in 2021, then spiked by 423.68% to $1.1 million in 2022, then surged by 211.56% to $3.4 million in 2023, then surged by 107.16% to $142,000 in 2024.
  • Its Cash from Investing Activities was $142,000 in Q3 2024, compared to $2.2 million in Q2 2024 and $9.0 million in Q1 2024.